1,394 results on '"Armstrong, Annalee"'
Search Results
102. Gossamer unveils new pipeline plans a year after lead program fizzled out in phase 2
103. Protalix reaches agreement with FDA on Fabry data package, but resubmission of PRX--102 could be years out
104. Idorsia's Fabry med did what executives were expecting--it just didn't relieve the disease's hallmark burning pain
105. J&J's RSV vaccine offers 80% efficacy against severe illness in a race crowded by Big Pharmas
106. Novartis' BTK inhibitor steps up where other Big Pharmas have failed in autoimmune diseases
107. Laurent's COVID-19 pill fails phase 2, but data helps narrow down patients who may benefit
108. Editas' gene-editing data are finally ready for prime time--and early signals suggest vision improvement in some patients
109. Pfizer tightens DMD patient criteria after serious adverse events crop up in phase 3 gene therapy trial
110. How to rescue Big Pharma drug castoffs from the scrap bin through nonprofit partnerships: report
111. Pfizer tests oral COVID-19 antiviral for preventing infection in people living with patients
112. If CytoDyn can't get leronlimab approved, these shareholders have a bold plan to tap Big Pharma
113. Capricor's DMD therapy slows disease progression in older patients, securing move to phase 3
114. Solid Bio hopes a shred of positive DMD data will spark a much-needed rally after clinical hold drama
115. SAB Biotherapeutics banks $60M more in funding from U.S. officials for COVID-19 antibody
116. Facing backlash from scientific community, Cassava drops interim Alzheimer's data with plenty of caveats
117. Novartis doesn't think optogenetics will completely cure blindness--but its new biotech is going to give it a try
118. Q&A: Eli Lilly is making strides in overall trial diversity, but oncology lags behind
119. Excision's CRISPR gene editing therapy for HIV is heading into human testing after FDA clearance
120. Intellia's ex vivo gene editing candidate for cancer cleared by FDA for human studies
121. Biogen's non-opioid painkiller drops another phase 2 trial, this time in sensory pain disorder
122. Amylyx can proceed with ALS submission to FDA afterall, marking a win for patients' advocacy efforts
123. Independent report confirms sexual harassment claims against anti-aging researcher de Grey
124. Bellus offers a scrap of analysis for chronic cough candidate in first-to-market battle with Merck
125. Cardiff reveals early data on challenger to Amgen's KRAS crown
126. Lexeo keeps foot on the gas pedal with $100M financing to follow up Stelios buy
127. Moderna donates ultra-rare disease therapy to nonprofit founded by late Takeda R&D chief
128. Eli Lilly's Alzheimer's moment has arrived after Biogen plows through the FDA gates
129. Pliant's lung disease drug is getting where it needs to be, but efficacy data is still to come
130. FDA committee takes on complex gene therapy safety questions with Novartis' Zolgensma providing lessons learned
131. Forte searching for new direction after only therapy flunks midstage atopic dermatitis trial
132. Bristol Myers greenlights neurodegenerative medicine from Evotec pact for $20M
133. The mRNA era has arrived thanks to COVID-19. What's next in the pipeline?
134. Fierce Biotech Fundraising Tracker '24: Ottimo raises $140M series A; SiteOne snags $100M.
135. Fierce Biotech Fundraising Tracker '24: Veradermics vaults with $75M; Angitia adds $120M.
136. Fierce Biotech Fundraising Tracker '24: Nuvig nabs $161M series B; Antag advances with $84M series A.
137. Key vaccine leaders departing FDA as COVID-19 booster questions linger
138. Roche-backed AC Immune finds even mixed-bag Alzheimer's data are enough to make shares explode
139. Lab named by Cassava to back up Alzheimer's data says they weren't involved, sending biotech's shares into freefall again
140. Inovio heads to Brazil for phase 3 COVID-19 vaccine trial, months after U.S. sent biotech packing
141. Cassava defends Alzheimer's science after citizen petition raises 'grave concerns' about clinical studies
142. Anti-aging foundation SENS fires de Grey after allegations he interfered with investigation into his conduct
143. Merck's $4.2B bintrafusp alfa nabs a 3rd strike. Is the GSK-partnered cancer hopeful out?
144. Migraine market better make way for AbbVie, as oral preventive atogepant poised to slice off $1.2B in sales
145. Sesen Bio shares crater after report of trial misconduct for bladder cancer drug
146. Regenerative medicine nears banner year with $14.1B cash infusion, regulatory milestones and a well-stocked pipeline
147. Qualigen calls it quits on COVID antiviral after pouring millions into R&D
148. Longeveron drug didn't help with aging frailty, but executives see late efficacy showing as a good sign
149. CytoDyn's previous HIV filing snafu now on better course after FDA sets them straight
150. I-Mab thinks cytokine storm drug can take on Humanigen's lenzilumab in sickest COVID-19 patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.